Ignota Labs Secures £5.5M to Tackle Drug Safety Failures
Deal News | Feb 26, 2025 | Business Cloud
Ignota Labs, a London-based MedTech company specializing in AI-driven drug development, has successfully closed a £5.5 million seed funding round. The company aims to expand its pipeline by acquiring additional distressed assets and advancing its first asset, a PDE9A inhibitor, into early-stage clinical trials. Ignota Labs utilizes deep learning and bioinformatics to address drug safety failures, a significant challenge leading to the abandonment of over 56% of drugs annually, causing $400 billion in losses for the pharmaceutical industry. The funding round was co-led by Montage Ventures and AIX Ventures, with participation from Modi Ventures, Blue Wire Capital, and Gaingels. Ignota Labs plans to use its SAFEPATH platform to identify and resolve molecular and biological issues, re-engineering therapies to save promising drugs from abandonment and reduce development timelines and costs.
Sectors
- MedTech
- Pharmaceuticals
- Venture Capital
Geography
- United Kingdom – Ignota Labs is based in London, making the UK a relevant geography for the company's operations and the location of the funding round.
- United States – Several of the venture capital firms involved, such as Montage Ventures, are likely based in or have significant operations in the United States.
Industry
- MedTech – The article revolves around the medical technology sector, focusing on developments in drug safety and AI-driven medical solutions.
- Pharmaceuticals – The discussion on drug development and safety issues relates directly to the pharmaceutical industry's challenge with drug toxicity.
- Venture Capital – The seed funding round and involvement of multiple investors highlight the venture capital industry's role in financing MedTech innovations.
Financials
- £5.5 million – The total amount raised in Ignota Labs' seed funding round.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Ignota Labs | Target Company | Company | A London-based MedTech company focused on AI-driven drug development to address drug safety failures. |
| Montage Ventures | Co-lead Investor | Company | A venture capital firm co-leading the seed funding round for Ignota Labs. |
| AIX Ventures | Co-lead Investor | Company | A venture capital firm co-leading the seed funding round for Ignota Labs. |
| Modi Ventures | Investor | Company | A participant in the seed funding round for Ignota Labs. |
| Blue Wire Capital | Investor | Company | A participant in the seed funding round for Ignota Labs. |
| Gaingels | Investor | Company | A participant in the seed funding round for Ignota Labs. |
| Sam Windsor | CEO and Co-founder | Person | CEO and co-founder of Ignota Labs, highlighting the company's mission in drug safety. |